Enhancing Intranasal Delivery and Bioavailability of Dihydroergotamine Utilizing Chitosan Nanoparticles

Figure 4

Plasma concentration versus time profile following 0.5 mg/kg intravenous, intranasal administration of DHE solution, and DHE loaded in chitosan nanoparticles (DHE-CS NP). Values are means ± SD (n = 3).